Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 8/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 8/20 | 0.64 |
| ▸ | ATR | Q13535 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070849 | 0.97 | CYP4F2 (0.65) | CYP4F2CYP4A11ATR | |
| SCHEMBL22070695 | 0.91 | CYP4F2 (0.65) | CYP4F2CYP4A11ATRMEN1KMT2A | |
| SCHEMBL22071090 | 0.90 | CYP4F2 (0.64) | CYP4F2CYP4A11ATRMEN1KMT2A | |
| SCHEMBL22070830 | 0.88 | CYP4F2 (0.65) | CYP4F2CYP4A11ATR | |
| SCHEMBL22071040 | 0.87 | CYP4F2 (0.65) | CYP4F2CYP4A11ATRMEN1KMT2A | |
| SCHEMBL22070639 | 0.87 | CYP4F2 (0.65) | CYP4F2CYP4A11ATRMEN1KMT2A | |
| SCHEMBL22070777 | 0.87 | CYP4F2 (0.61) | CYP4F2CYP4A11ATR | |
| SCHEMBL22071026 | 0.86 | CYP4F2 (0.60) | CYP4F2CYP4A11ATR | |
| SCHEMBL23309163 | 0.86 | CYP4F2 (0.62) | CYP4F2CYP4A11ATR | |
| SCHEMBL23309162 | 0.86 | CYP4F2 (0.62) | CYP4F2CYP4A11ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885ATR 4013/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | CYP4F2 20/4885CYP4A11 2/4885ATR 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.